Last Updated: November 16, 2026

Details for Patent: 10,940,146

« Back to Dashboard


Which drugs does patent 10,940,146 protect, and when does it expire?

Patent 10,940,146 protects XPHOZAH and is included in one NDA.

This patent has fifty-four patent family members in twenty-eight countries.

Summary for Patent: 10,940,146
Title:NHE3-binding compounds and methods for inhibiting phosphate transport
Abstract:Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Inventor(s):Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
Assignee: Ardelyx Inc
Application Number:US16/351,225
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,940,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ardelyx Inc XPHOZAH tenapanor hydrochloride TABLET;ORAL 213931-001 Oct 17, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF HYPERPHOSPHATEMIA ⤷  Start Trial
Ardelyx Inc XPHOZAH tenapanor hydrochloride TABLET;ORAL 213931-001 Oct 17, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF SERUM PHOSPHORUS IN ADULTS ⤷  Start Trial
Ardelyx Inc XPHOZAH tenapanor hydrochloride TABLET;ORAL 213931-002 Oct 17, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial REDUCTION OF SERUM PHOSPHORUS IN ADULTS ⤷  Start Trial
Ardelyx Inc XPHOZAH tenapanor hydrochloride TABLET;ORAL 213931-002 Oct 17, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF HYPERPHOSPHATEMIA ⤷  Start Trial
Ardelyx Inc XPHOZAH tenapanor hydrochloride TABLET;ORAL 213931-003 Oct 17, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial REDUCTION OF SERUM PHOSPHORUS IN ADULTS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,940,146

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 095852 ⤷  Start Trial
Australia 2014250956 ⤷  Start Trial
Australia 2019204676 ⤷  Start Trial
Brazil 112015025805 ⤷  Start Trial
Canada 2909169 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.